CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Cash flows from operating activities
Net (loss) income	$ (9,043)	$ 10,837
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	697	276
Stock-based compensation expense	2,235	3,159
Bad debt expense, net of recoveries	2,350	1,023
Loss on disposition of assets	63	0
Noncash amortization of debt discount	409	369
Noncash interest expense associated with convertible debt	0	243
Noncash change in fair value of derivatives	(295)	(36,264)
Other	(1)	15
Changes in operating assets and liabilities:
Accounts receivable	(2,461)	(675)
Prepaid expenses and other current assets	(467)	(2,222)
Accounts payable	(16)	173
Accrued expenses and other current liabilities	(3,246)	(2,141)
Deferred revenue	137	77
Net cash used in operating activities	(9,638)	(25,130)
Cash flows from investing activities
Additions of property, equipment, and software	(1,042)	(2,194)
Proceeds from sale of property and equipment	27	0
Net cash used in investing activities	(1,015)	(2,194)
Cash flows from financing activities
Proceeds from exercise of stock options	0	158
Proceeds from convertible promissory notes	0	29,374
Proceeds from business combination placed in escrow and restricted	0	39,032
Trust proceeds received from recapitalization at closing	0	582
Issuance of common Stock under ESPP	168	0
Repurchase of common stock and settlement of forward purchase agreements	0	(31,303)
Transaction costs associated with recapitalization	0	(10,761)
Advances (repayments) of related party payables	1	(17)
Net cash provided by financing activities	169	27,065
Net decrease in cash, cash equivalents, and restricted cash	(10,484)	(259)
Cash, cash equivalents, and restricted cash, beginning of period	25,202	28,695
Cash, cash equivalents, and restricted cash, end of period	14,718	28,436
Supplemental disclosure of non-cash financing activities
Stockholder contribution for debt issuance costs	0	924
Repurchase of common stock in other accrued expenses	0	360
Conversion of promissory notes into common stock	0	33,024
Issuance of forward share purchase agreements	0	14,170
Issuance of private warrants	0	3,916
Issuance of sponsor shares subject to earn-out conditions	0	6,867
Issuance of stockholder earn-out rights	$ 0	$ 26,131